24
Jan 2026
Microbiome differences distinguish preterm infants with parenteral nutrition-associated cholestasis
Microbiome differences distinguish preterm infants with parenteral nutrition-associated cholestasis
Cancer Research
Strategic Partnerships
Mercury Pharmaceuticals business strategy is to focus on internal research and development strengths to validate product candidates through proof of concept in cancer patients. We offer access to discovery expertise and product candidates in areas of unmet medical need and distinct commercial value.
Mercury Pharmaceuticals is willing to secure partnerships to enhance our combined ability to advance novel science and accelerate the development of differentiated therapeutics. Our broad intellectual property portfolio and unique research approach enable us to be a productive partner for those seeking to advance meaningful therapeutics in cancer biology, translational oncology, and cancer prevention and control studies.
Mercury Pharmaceuticals has a strategic alliance agreement with Aesica Pharmaceuticals to advance the clinical development for the treatment of ovarian cancer and to collaborate on preclinical studies of MP13920 as a treatment for breast cancer based on positive results from a Phase 2 trial of MP13920 in ovarian cancer patients resistant to paclitaxel (Taxol), the standard of care for this disease.
If interested in learning more, please send us a message.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
24
Jan 2026
Colorblindness linked to delayed bladder cancer detection and higher mortality
Recognizing the sight of blood in urine, the most common first sign of bladder cancer, is often the impetus that leads people to a diagnosis.
24
Jan 2026
Firefighter protective gear restricts movement and may increase injury risk
When firefighters respond to an emergency, the gear they wear to protect themselves can also create challenges that could jeopardize their performance and safety.
24
Jan 2026
Selective inhibition of cPLA2 shows promise against Alzheimer's-related brain inflammation
A multidisciplinary USC research team has identified new compounds that may target a key driver of brain inflammation linked to Alzheimer's disease. Their research just published in the Nature publication npj Drug Discovery.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.